Chinese Journal of Cancer Research

Scope & Guideline

Connecting knowledge to innovation in cancer research.

Introduction

Welcome to your portal for understanding Chinese Journal of Cancer Research, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN1000-9604
PublisherCHINESE JOURNAL CANCER RESEARCH CO
Support Open AccessNo
Country-
TypeJournal
Convergefrom 1988 to 1996, from 1998 to 2017 (coverage discontinued in Scopus)
AbbreviationCHINESE J CANCER RES / Chin. J. Cancer Res.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressLTD PEKING U CANCER HOSP & INST, NO 52, FUCHENG RD, HAIDIAN, BEIJING 100142, PEOPLES R CHINA

Aims and Scopes

The Chinese Journal of Cancer Research aims to advance the understanding of cancer through rigorous research, focusing on a blend of clinical and translational studies. The journal serves as a platform for disseminating significant findings that can enhance the prevention, diagnosis, and treatment of cancer, particularly within the Chinese population.
  1. Clinical Oncology:
    The journal emphasizes clinical research, particularly the efficacy and safety of novel therapies, clinical trials, and treatment protocols for various cancers, including gastric, lung, and colorectal cancers.
  2. Molecular and Genetic Studies:
    Research on the molecular mechanisms underlying cancer progression, genetic susceptibility, and tumor markers is a core focus, contributing to personalized medicine and targeted therapies.
  3. Immunotherapy and Immune Microenvironment:
    There is a strong emphasis on studies related to cancer immunotherapy, immune evasion, and the tumor microenvironment, reflecting the growing importance of immunological approaches in cancer treatment.
  4. Epidemiology and Risk Factors:
    The journal publishes epidemiological studies that investigate cancer prevalence, risk factors, and screening strategies, particularly in the context of the Chinese population.
  5. Surgical Techniques and Innovations:
    Research on advancements in surgical methods, including minimally invasive techniques and their outcomes in cancer treatment, is a significant aspect of the journal's scope.
  6. Guidelines and Consensus Statements:
    The journal frequently features updates and discussions on clinical guidelines, ensuring that practitioners are informed about the latest standards in cancer care.
Recent publications in the Chinese Journal of Cancer Research highlight several emerging themes and trends that reflect the evolving landscape of cancer research and treatment. These trends indicate a shift towards more innovative and integrative approaches to understanding and managing cancer.
  1. Integration of Genomics and Precision Medicine:
    There is a growing emphasis on genomic studies and precision medicine, indicating a trend towards personalized treatment strategies based on individual genetic profiles.
  2. Research on Minimal Residual Disease (MRD):
    Emerging studies on the detection and significance of minimal residual disease in various cancers suggest a trend towards improving treatment monitoring and outcomes.
  3. Focus on Microbiome and Cancer Interactions:
    Increasing interest in the role of the microbiome in cancer progression and treatment response reflects a broader understanding of the factors influencing cancer biology.
  4. Innovative Surgical Techniques:
    A trend towards exploring and validating novel surgical techniques, particularly minimally invasive approaches, showcases the journal's commitment to advancing surgical oncology.
  5. Patient-Centric Studies and Quality of Life Assessments:
    There is a notable increase in studies focusing on patient-reported outcomes, symptom management, and quality of life in cancer patients, highlighting a shift towards more holistic cancer care.

Declining or Waning

While the journal continues to cover a wide range of cancer-related topics, some areas appear to be diminishing in frequency or focus. This may reflect shifting priorities in cancer research or changes in clinical practice.
  1. Traditional Chemotherapy Studies:
    There is a noticeable decline in publications focused solely on traditional chemotherapy regimens, as the field shifts towards personalized and targeted therapies.
  2. Radiotherapy Alone Without Combination Approaches:
    Research on radiotherapy as a standalone treatment has decreased, with a growing preference for studies that explore combined modalities, including immunotherapy.
  3. Basic Science Research:
    The journal has shown a waning interest in basic science research unrelated to clinical applications, as more emphasis is placed on translational and clinical studies that have direct implications for patient care.

Similar Journals

Thoracic Cancer

Fostering collaboration for lung cancer solutions.
Publisher: WILEYISSN: 1759-7706Frequency: 24 issues/year

Thoracic Cancer is a distinguished open-access journal published by WILEY, dedicated to advancing the field of thoracic oncology. Since its establishment in 2010, the journal has emerged as a crucial platform for the dissemination of innovative research and clinical studies relating to lung cancer and other thoracic malignancies. With a commendable impact reflected in its 2023 Q2 rankings in the categories of Medicine (Miscellaneous), Oncology, and Pulmonary and Respiratory Medicine, the journal features high-quality articles that are vital for researchers, clinicians, and students aspiring to enhance their understanding of thoracic cancers. Operating out of Australia, Thoracic Cancer has embraced a commitment to open access since 2015, ensuring that vital research is readily available to a global audience. The journal's rigorous peer-review process and emphasis on novel findings make it an indispensable resource for professionals seeking to stay at the forefront of this rapidly evolving field.

BRITISH JOURNAL OF CANCER

Advancing Cancer Knowledge Through Rigorous Research.
Publisher: SPRINGERNATUREISSN: 0007-0920Frequency: 24 issues/year

The British Journal of Cancer, published by SpringerNature, stands as a preeminent resource in the fields of Cancer Research and Oncology, with a distinguished history of publication dating back to 1947. With its Q1 rank in both categories for 2023, this journal is among the top-tier publications, offering cutting-edge research and insights into the biology, etiology, and treatment of cancer. The journal’s rigorous peer-review process ensures that readers are presented with high-quality studies that contribute to the advancement of cancer knowledge and clinical practice. Operating from the United Kingdom, it has garnered a notable impact factor and ranks impressively within Scopus, making it an essential publication for researchers, healthcare professionals, and students who are dedicated to understanding cancer's complexities. Access to the journal's articles is available in traditional formats, providing a versatile platform for disseminating pivotal research. As we move towards a future where cancer treatment and prevention remain crucial, the British Journal of Cancer continues to play a vital role in shaping the dialogue and discoveries within the oncology community.

ONCOLOGY RESEARCH

Advancing the Frontiers of Cancer Research
Publisher: TECH SCIENCE PRESSISSN: 0965-0407Frequency: 6 issues/year

ONCOLOGY RESEARCH, published by TECH SCIENCE PRESS, is a vital academic journal dedicated to the rapidly evolving field of oncology. With its ISSN 0965-0407 and E-ISSN 1555-3906, the journal serves as a key resource for researchers, clinicians, and academicians committed to advancing cancer research and treatment strategies. Operating without an Open Access model, ONCOLOGY RESEARCH provides high-quality, peer-reviewed articles that cover diverse topics within cancer research, medicine, and oncology, with its 2023 Scopus ranking placing it in the Q3 quartile. The journal's commitment to facilitating rigorous scientific discourse is evident in its historical breadth, with a publishing history dating back to 1992. ONCOLOGY RESEARCH is not only significant for the academic community but also plays a critical role in fostering new insights and approaches in the fight against cancer, making it a must-read for those involved in this critical area of study.

CURRENT CANCER DRUG TARGETS

Connecting knowledge and innovation in cancer drug development.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1568-0096Frequency: 11 issues/year

CURRENT CANCER DRUG TARGETS is a prominent academic journal published by Bentham Science Publishers Ltd, focusing on the critical intersection of cancer research and innovative drug development. Since its inception in 2001, this journal has offered a platform for the dissemination of cutting-edge research aimed at advancing targeted cancer therapies, contributing significantly to the fields of Cancer Research, Drug Discovery, Oncology, and Pharmacology. With a respectable impact factor and consistent ranking in its respective categories, including Q2 in Drug Discovery and Pharmacology, it positions itself as an invaluable resource for researchers, clinicians, and students alike. CURRENT CANCER DRUG TARGETS is dedicated to enhancing our understanding of novel therapeutic targets and methods, thereby fostering a collaborative environment for knowledge exchange in the ever-evolving landscape of cancer treatment.

CELLULAR ONCOLOGY

Connecting Minds to Combat Cancer
Publisher: SPRINGERISSN: 2211-3428Frequency: 6 issues/year

CELLULAR ONCOLOGY is an esteemed open access journal published by SPRINGER since 2004, specializing in the dynamic field of oncological research. With its ISSN 2211-3428 and E-ISSN 2211-3436, this journal plays a pivotal role in disseminating cutting-edge findings and innovative methodologies that address cancer at the cellular level. The journal has consistently achieved high-impact recognition, currently holding a Q2 rating in Cancer Research and Q1 rankings in Medicine (miscellaneous), Molecular Medicine, and Oncology as of 2023. Furthermore, it ranks 56th in oncology medicine and 48th in cancer research according to Scopus, placing it firmly within the top echelons of its field. Published in the Netherlands, with an aim to connect scientists, clinicians, and practitioners worldwide, CELLULAR ONCOLOGY fosters a collaborative environment for researchers to share insights, enhance understanding, and advance treatments. The journal’s open access model ensures that ground-breaking research is freely available, facilitating greater visibility and impact within the scientific community and beyond.

Gastric Cancer

Pioneering Research in Gastric Oncology.
Publisher: SPRINGERISSN: 1436-3291Frequency: 4 issues/year

Gastric Cancer is a leading journal in the field of oncology, published by SPRINGER in Japan. With an ISSN of 1436-3291 and an E-ISSN of 1436-3305, this esteemed journal aims to disseminate high-quality research focused on all aspects of gastric cancer, including its pathophysiology, diagnosis, treatment, and prevention. As an indicator of its academic excellence, Gastric Cancer is ranked in the top quartile (Q1) for Cancer Research, Gastroenterology, Medicine (miscellaneous), and Oncology categories as of 2023. The journal holds impressive Scopus rankings, being positioned #9 in Gastroenterology and #34 in Oncology, demonstrating its critical role in shaping advancements within these disciplines. Although not an open-access publication, it provides various access options for institutions and individuals looking to elevate their understanding of gastric cancer. With a converged publication history from 2000 to 2024, it serves as a vital resource for researchers, professionals, and students dedicated to eradicating this formidable disease.

Trends in Cancer

Advancing Cancer Research with Insightful Innovations
Publisher: CELL PRESSISSN: 2405-8025Frequency: 12 issues/year

Trends in Cancer is a leading journal published by CELL PRESS, dedicated to advancing the field of cancer research and oncology. Since its inception in 2015, the journal has rapidly gained a reputation for excellence, securing both Q1 rankings in Cancer Research and Oncology categories for 2023 and boasting impressive Scopus ranks—#13 out of 404 in Medicine Oncology and #9 out of 230 in Biochemistry, Genetics and Molecular Biology, thus placing it in the top 4% of its field. The journal aims to publish high-quality, innovative research that offers new insights into cancer biology and treatment strategies. With a commitment to scholarly rigor and a broad scope that encompasses molecular mechanisms to therapeutic approaches, Trends in Cancer serves as an essential resource for researchers, professionals, and students eager to stay informed about the latest developments in cancer science. Although it is not an open-access journal, its contributions are pivotal in shaping the future of cancer research.

CANCER IMMUNOLOGY IMMUNOTHERAPY

Empowering Cancer Research through Immunological Discoveries
Publisher: SPRINGERISSN: 0340-7004Frequency: 12 issues/year

Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.

Cancers

Fostering collaboration in the fight against cancer.
Publisher: MDPIISSN: Frequency: 24 issues/year

Cancers is a leading peer-reviewed journal published by MDPI, dedicated to advancing the field of oncology and cancer research. Established in 2009 and based in Switzerland, this Open Access journal provides a platform for the rapid dissemination of high-quality research findings, reviews, and clinical studies related to all aspects of cancer biology and treatment. With an impressive impact factor and recognized as Q1 in Oncology and Q2 in Cancer Research for 2023, Cancers strives to foster a collaborative environment among researchers, healthcare professionals, and students seeking to deepen their knowledge and understanding of cancer. The journal’s commitment to accessibility and its broad scope make it an invaluable resource for anyone passionate about combating cancer and improving patient outcomes. For more information and to access its diverse publications, visit the journal’s website.

Cancer Communications

Pioneering Discoveries in Cancer Communications
Publisher: WILEYISSN: Frequency: 12 issues/year

Cancer Communications, published by WILEY, is a leading open-access journal that has positioned itself at the forefront of cancer research and oncology since its inception in 2017. With an impressive HIndex reflective of its scholarly impact and recognized in the Q1 category for both Cancer Research and Oncology as of 2023, this journal consistently ranks in the top echelons of its field, specifically at Rank #16/404 and Rank #13/230 in their respective categories on Scopus. Cancer Communications aims to disseminate cutting-edge research findings, innovative methodologies, and significant advancements in cancer treatments, thereby fostering a deeper understanding of oncology among researchers, healthcare professionals, and students. The journal operates under an Open Access model since 2018, ensuring that vital research is accessible to a global audience, thus enhancing collaboration and knowledge sharing necessary to tackle one of the most pressing health challenges of our time. Located in Hoboken, NJ, United States, and with a strong commitment to scientific excellence, Cancer Communications remains an essential resource for anyone engaged in the fight against cancer.